Clinical characteristics of dermatologic manifestations of COVID‐19 infection

Clinical characteristics of dermatologic manifestations of COVID‐19 infection

This article co-authored by Cromos Pharma CEO Dr Vlad Bogin and published in the International Journal of Dermatology (3 July 2020) examines the dermatologic manifestations of COVID-19. It includes a case series of 15 patients, review of literature, and proposed etiological classification. Read the full article here

CONTACT

INQUIRY@CROMOSPHARMA.COM

To arrange an introductory meeting and find out how our experience can benefit your next clinical project.

OUR PUBLICATIONS

The Most Impactful FDA Drug Approvals of 2024 | Cromos Pharma
The Most Impactful FDA Drug Approvals of 2024: A Transformative Year for Biopharma
Top 12 Clinical Trials 2024: Transforming the Future of Medicine | Cromos Pharma
2024’s Top 12 Clinical Trials: Transforming the Future of Medicine
Key Takeaways from ASH 2024 | Cromos Pharma
Reflections on ASH 2024: Transformative Breakthroughs in Hematology-Oncology
Insights into Hospital Systems and Regulatory Framework in Türkiye | Cromos Pharma
Exploring Türkiye’s Edge in Clinical Research: Insights into Hospital Systems and Regulatory Framework
Clinical Research Focus 33rd edition | Cromos Pharma
Clinical Research Focus. 35th Edition
Meet Cromos Pharma at ASH 2024
Countdown to ASH 2024: What to Expect in Breakthroughs in Hematology-Oncology
AI in Clinical Trials | Cromos Pharma
AI in Clinical Trials: 8 Groundbreaking Innovations That Defined the Year
Lung Cancer Care: New Treatment Insights | Cromos Pharma
Advancing Lung Cancer Care: New Treatment Insights Highlighted During Awareness Month
World Diabetes Day Focus: The Role of GLP-1 Agonists and SGLT2 Inhibitors in Diabetes Treatment | Cromos Pharma
World Diabetes Day Focus: The Role of GLP-1 Agonists and SGLT2 Inhibitors in Diabetes Treatment
Changing Defibrillator Pad Placement Increase Survival by 164% | Cromos Pharma
Changing Defibrillator Pad Placement Increases Survival by 164%
Stem Cells Therapy Offers New Hope for Type 1 Diabetes | Cromos Pharma
Groundbreaking Stem Cell Therapy Offers New Hope for Type 1 Diabetes: A Medical Breakthrough
How the EU CTR is Shaping the Future of Clinical Trials | Cromos Pharma
How the EU CTR is Shaping the Future of Clinical Trials: Insights and Key Challenges for Sponsors
Data Protection Representative: Understanding GDPR's Article 27 Requirement | Cromos Pharma
Do You Need a Data Protection Representative? Understanding GDPR’s Article 27 Requirement
GDPR Essentials: Data Protection Officer | Cromos Pharma
GDPR Essentials: What You Need to Know About Appointing a Data Protection Officer
Mastering EU Regulatory Compliance | Part 1 | Cromos Pharma
Mastering EU Regulatory Compliance: Key Roles of the LR, DPO, and DPR in Clinical Trials (Part 1)
World Mental Health Day | Cromos Pharma
World Mental Health Day: How Clinical Trials are Transforming Mental Health Treatments for the Future
Clinical Research Focus 33rd edition | Cromos Pharma
Clinical Research Focus. 33rd Edition
7 Breakthroughs to Watch This World Heart Day | Ai | Cromos Pharma
How AI is Revolutionizing Heart Health: 7 Breakthroughs to Watch This World Heart Day
Clinical Trials in Portugal | Cromos Pharma
Exploring Portugal’s Clinical Trials Landscape: Innovations, Infrastructure, and Opportunities
7 Reasons to Choose Central and Eastern Europe | Cromos Pharma
7 Reasons to Choose Central and Eastern Europe as Your Go-To Destination for Clinical Trials
Clinical Research Focus 32nd edition | Cromos Pharma
Clinical Research Focus. 32nd Edition
Ozempic’s Potential Link to Suicidal Thoughts | Cromos Pharma
New Study Raises Concerns Over Ozempic’s Potential Link to Suicidal Thoughts
New Research Alert: Alarming Trends in Men’s Cancer Incidence & Projections to 2050 | Cromos Pharma
New Research Alert: Alarming Trends in Men’s Cancer Incidence & Projections to 2050
Poland: Europe’s New Hub for Clinical Research | Cromos Phama
Poland: Europe’s New Hub for Clinical Research
Clinical Research Focus 31st edition | Cromos Pharma
Clinical Research Focus. 31st Edition
Revolutionary HIV Breakthrough: Is Lenacapavir the Ultimate Game-Changer? | Cromos Pharma
Revolutionary HIV Breakthrough: Is Lenacapavir the Ultimate Game-Changer?
Why Smaller CROs Are the Key to Big Wins | Cromos Pharma
Unleashing Biotech Success: Why Smaller CROs Are the Key to Big Wins
PMBoK, ISO 9001, and ICH GCP: Three Pillars of Quality in Clinical Research | Cromos Pharma
PMBoK, ISO 9001, and ICH GCP: Three Pillars of Quality in Clinical Research
Clinical Research Focus 30th edition | Cromos Pharma
Clinical Research Focus. 30th Edition
Transform Clinical Trial Practices with ICH GCP E6 R3 | Cromos Pharma
Major Enhancements Set to Transform Clinical Trial Practices with ICH GCP E6 R3